Skip to main content
. 2021 Feb 10;26(5):366–374. doi: 10.1002/onco.13697

Figure 2.

Figure 2

(A): The percentage of patients reporting any (solid) numbness and tingling in the hands and feet and those reporting greater severity of symptoms in the hands and feet (dash). (B): The percentage of patients reporting functional impairments in the upper limb (difficulty manipulating objects) and lower limb (problems walking) during paclitaxel treatment (0–12 weeks) and postcompletion (3–12 months)